What Is It About? {#sec1_1}
=================

-   The pathomechanism of angiotensin-converting enzyme (ACE) inhibitor-induced angioedema is not yet fully understood. Bradykinin seems to play a major role in the development of edema.

-   We aimed to analyze the influence of ACE inhibitor treatment on C1-inhibitor (C1-INH) levels. Two study sections were included: captopril was added to blood samples of 5 healthy subjects, and C1-INH levels were measured. The second section was done with 17 patients who received therapy with an ACE inhibitor.

-   A dose-dependent effect on C1-INH levels in captopril-incubated blood samples of healthy test persons was shown. In patients with ACE inhibitor treatment, heterogeneous reactions of C1-INH values were detected.

Introduction {#sec1_2}
============

Angiotensin-converting enzyme (ACE) inhibitors are frequently prescribed drugs for the therapy of primary hypertension and heart failure with a reduced ejection fraction. They inhibit the conversion of angiotensin I into angiotensin II and are expected to prevent cardiovascular, cerebrovascular, and renal complications associated with persistent high blood pressure as well as deterioration of heart failure \[[@B1], [@B2]\].

ACE inhibitor-induced (ACEi) angioedema (AE) is a rare side effect. A systematic investigation of epidemiological studies found an estimated prevalence of ACEi AE between 0.7 and 1.7 per 10,000 inhabitants in the USA and between 1.0 and 2.6 per 10,000 inhabitants in Germany \[[@B3]\]. The weighted incidence of AE due to ACE inhibitor treatment was 0.3% in a large meta-analysis of randomized trials \[[@B4]\]. Interestingly, the risk of ACEi AE is significantly increased in African Americans \[[@B4], [@B5]\].

ACEi AE is predominantly located in the head and neck region, i.e., the lips, face, tongue, pharynx, and larynx \[[@B6]\]. AE manifestation in the upper airway region can be life-threatening due to its unpredictable clinical course. ACE is one of the main degradation enzymes of bradykinin -- therefore, it is assumed that the iatrogenic inhibition of ACE leads to an increase in bradykinin levels \[[@B7]\]. Bradykinin in turn signals mainly via the constitutively expressed bradykinin receptor B~2~ (B2R) and leads to vasodilatation and increases vascular permeability \[[@B8]\]. The downstream mechanisms of bradykinin include the phospholipase C pathway, leading to inositol triphosphate formation and intracellular Ca^2+^ mobilization, and the phospholipase A2 pathway, resulting in arachidonic acid release; bradykinin furthermore stimulates endothelial nitric oxide synthase \[[@B9], [@B10], [@B11]\]. However, it remains unclear which of these signal transduction events are involved to a greater or lesser extent in nonallergic AE.

In the majority of patients, ACEi AE develops in the first weeks of treatment; nevertheless, it can occur even after several years of uneventful ACE inhibitor treatment \[[@B6], [@B12]\]. There is no officially approved therapy for ACEi AE. Therefore, it is often primarily treated the same way as mast cell-mediated AE, i.e., with glucocorticoids and antihistamines. In severe cases -- and if available -- the B2R antagonist icatibant or a C1-inhibitor (C1-INH) concentrate can be applied. Both therapies have been approved over the years for the therapy of hereditary AE (HAE), a rare autosomal dominant disorder caused by a mutation in the C1-INH coding gene *SERPING1* \[[@B13], [@B14]\]. C1-INH -- a member of the serine protease inhibitor (serpin) family -- has a breaking function in the synthesis of bradykinin \[[@B15]\]. In HAE, C1-INH is either deficient (decreased C1-INH concentration and C1-INH activity) or nonfunctioning (normal or increased C1-INH concentration but decreased C1-INH activity), leading to uncontrolled generation of bradykinin. A third and rarer form of HAE with normal C1-INH levels is likely mediated by increased activity of factor XII due to a mutation inducing defective glycosylation \[[@B16]\].

Based on current research results, it is discussed whether icatibant and C1-INH concentrate are effective in the acute treatment of ACEi AE. The available studies show inconsistent data; nevertheless, a high proportion of publications report successful treatment of ACEi AE with intravenous C1-INH or subcutaneous administration of icatibant \[[@B17], [@B18], [@B19], [@B20]\].

We analyzed laboratory results from patients who presented with acute ACEi AE. In 8 inpatient cases during the last 3 years, we analyzed C1-INH values and ACE activity in blood samples and found increased C1-INH activity while -- as expected -- ACE activity was decreased (Table [1](#T1){ref-type="table"}). In the present study, we aimed to analyze the influence of ACE inhibitor treatment on C1-INH levels.

Methods {#sec1_3}
=======

Section 1: Blood Samples of Healthy Subjects {#sec2_1}
--------------------------------------------

Inclusion criteria were the absence of a diagnosis of HAE and no present or planned therapy with an ACE inhibitor. Only adult persons were included. Immunosuppressive therapy and/or acute or chronic inflammation were exclusion criteria.

The primary endpoints were the change in C1-INH activity and the C1-INH concentration after addition of the ACE inhibitor captopril. The secondary endpoint was the dose dependency (ACE inhibitor dose and the change in ACE activity). There were two reasons why captopril was chosen as the ACE inhibitor: (1) the prodrug of captopril needs no enzymatic activation and (2) it is soluble in water.

Three citrate containers (each 2.7 mL) and 3 serum tubes (each 4.9 mL) were filled with blood from each subject. One citrate container and 1 serum tube are needed for measurement of C1-INH activity, the C1-INH concentration, and ACE activity. One citrate container and 1 serum tube from each test person were directly incubated as a control for 180 min (37°C, 4% CO~2~), centrifuged (4,400 rpm, 15 min, 20°C), frozen (--20°C), and sent to the specialized laboratory Dr. Limbach & Kollegen, Heidelberg, Germany. To 1 citrate container and 1 serum tube from each subject, 5 mg captopril was added; to the remaining pair of tubes, 25 mg captopril was added. They were all incubated for 180 min (37°C, 4% CO~2~), then centrifuged (4,400 rpm, 15 min, 20°C), frozen (--20°C), and sent to the abovementioned laboratory. The experimental setup was based upon methods from a dissertation about the influence of ACE inhibitors on cellular function \[[@B21]\].

Section 2: Blood Samples of Patients before and after ACE Inhibitor Therapy {#sec2_2}
---------------------------------------------------------------------------

The second section was performed in cooperation with the Department of Cardiology, Internal Medicine II, Ulm University Medical Center, Ulm, Germany, to find and recruit patients with ACE inhibitors as new regular treatment. The inclusion and exclusion criteria were the same as mentioned above, except that planned therapy with an ACE inhibitor was a fundamental inclusion criterion.

The primary endpoints were the changes in C1-INH activity and concentration 24 h and at least 4 weeks after ACE inhibitor treatment initiation. Three dates were settled for collecting blood samples of the patients: before starting the ACE inhibitor therapy (study visit 1), 24 h after first medication intake (study visit 2), and 4 weeks later (study visit 3). The blood samples consisted of 2 serum tubes and 1 citrate container each. All blood samples were sent for C1-INH value analysis to the laboratory Dr. Limbach & Kollegen.

Statistical analysis of both study sections was done using IBM SPSS Statistics 21 and by performing an analysis of variance (ANOVA). Statistical significance was set at *p* \< 0.05.

Results {#sec1_4}
=======

Section 1 {#sec2_3}
---------

Five healthy test persons (3 female and 2 male) were included in the first study section. The age range of the subjects was 26--43 years, and the average age was 33 years.

The values for C1-INH activity and C1-INH concentration stayed almost constant after addition of 5 mg captopril and 180 min of incubation in comparison to 180 min of incubation alone (Table [2](#T2){ref-type="table"}).

After addition of 25 mg captopril, a significant decrease in C1-INH concentration was found in all test persons (ANOVA, *p* = 0.002; Fig. [1](#F1){ref-type="fig"}). In only 1 subject, the decrease was slightly below the normal range (0.16 g/L; normal range: 0.17--0.44 g/L), whereas the other 4 test persons presented values within the normal range.

We also observed a significant decrease in C1-INH activity in all subjects after addition of 25 mg captopril and 180 min of incubation (ANOVA, *p* = 0.004; Fig. [2](#F2){ref-type="fig"}). In 4 of the 5 test persons, the decrease was below the normal range.

Section 2 {#sec2_4}
---------

Seventeen patients (5 female and 12 male) were included in the second part of the study. The age range of the participants was 39--81 years, and the average age was 61 years. All patients received their first ACE inhibitor therapy with ramipril either at the Department of Otorhinolaryngology, Head and Neck Surgery, or at the Department of Cardiology, Internal Medicine II, Ulm University Medical Center. The dosage of ramipril ranged between 2.5 and 10 mg daily. Unfortunately, 7 patients did not complete the third study visit after at least 4 weeks; thus, only data from 10 patients were analyzed concerning "long-term" effects. Five patients failed to appear, 1 patient had to change the ACE inhibitor to an alternative therapy due to dry cough, and 1 patient stopped the therapy due to hypotonic blood pressure values.

Among the measurements of C1-INH values in the second study part, no significant change could generally be detected (Fig. [3](#F3){ref-type="fig"}). The most frequently observed effects were increases in C1-INH activity and C1-INH concentration, but the effects on both C1-INH values were individual and incoherent. In the following, the second study visit is described as an example: in 9 patients, C1-INH activity and the C1-INH concentration increased 24 h after the first ramipril administration, in 2 patients a decrease in both values was detected, 4 patients showed no change in either C1-INH activity or C1-INH concentration, and in 2 patients one of the two laboratory values had decreased and one increased. All the results are summarized in Figure [3](#F3){ref-type="fig"}.

We performed a correlation analysis between C1-INH activity and C1-INH concentration. There was a strong positive correlation at study visit 1 (*r* = 0.929, *p* = 0.01; Pearson), at study visit 2 (*r* = 0.898, *p* = 0.01; Pearson), and at study visit 3 (*r* = 0.850, *p* = 0.01; Pearson).

We tried to find any correlations with comorbidities, sex, side effects, other medication intake, or any known patient characteristics. Two interesting findings will be mentioned, but as the cohort was too small to form subgroups, larger studies are needed to ascertain whether any further statements can be made based on these findings. One patient (P7; Fig. [3](#F3){ref-type="fig"}) developed dry cough as a side effect, which is why the medication had to be changed and only the second study visit after 24 h could be performed. This patient was one of the 4 patients with no change in either C1-INH activity or concentration. Another patient (P2; Fig. [3](#F3){ref-type="fig"}) had sitagliptin as the regular medication. Sitagliptin inhibits dipeptidyl peptidase 4, another enzyme for bradykinin degradation. This patient exhibited a comparatively strong increase in both C1-INH activity and C1-INH concentration.

In the second study part, no correlation between the prescribed ramipril dosages and the C1-INH values could be observed.

Discussion {#sec1_5}
==========

The evaluation of molecular markers that characterize ACEi AE and the search for predictors of the risk of developing an ACEi AE are elemental parts of AE research projects \[[@B22], [@B23]\]. To date, no convincing marker has been found or taken over into clinical routine. Based on the findings in 8 patients with ACEi AE, we analyzed the influence of ACE inhibition on C1-INH values in two study parts.

In the first study section, we observed a significant and dose-dependent decrease in C1-INH concentration and C1-INH activity 3 h after addition of 25 mg captopril to the blood samples of all subjects. A possible explanation for this finding is that elevated bradykinin levels lead to an increased use of C1-INH, and as C1-INH is primarily synthesized in the liver and also produced in monocytes, skin fibroblasts, and endothelial cells \[[@B15]\], C1-INH cannot be refilled in vitro. Therefore, a state of consumption explains the significantly decreased C1-INH values 3 h after addition of 25 mg captopril. The present results clearly demonstrate an interaction between ACE inhibition and C1-INH values, but also the limitations of an in vitro setting for this purpose.

The second study section with patients new on ACE inhibitor treatment showed individual courses of C1-INH concentrations and C1-INH activity. In our small group of patients, no association with any of the clinical characteristics could be detected. It is obvious that a higher number of patients are needed to carry out further statistical evaluations. Returning to the initial question, the individual courses of C1-INH values before and after ACE inhibitor treatment do not exclude them from their use as a biomarker for ACEi AE, but this requires further investigation.

To our knowledge, we are the first to describe an increase in C1-INH activity during acute ACEi AE attacks (Table [1](#T1){ref-type="table"}), a fact that was observed in routinely taken blood samplings from 8 inpatient cases. Two of the patients presented with remarkably high C1-INH activity values, albeit still within the normal range (111 and 122%; normal range: 70--130%), whereas the other 6 patients showed C1-INH activity above the upper limit of 130%. In HAE, a disorder which is also mediated by bradykinin, the role of C1-INH is relatively well known, whereas in the pathomechanism of ACEi AE the function of C1-INH is unclear. In C1-INH-deficient mice, it was shown that inhibition of bradykinin inactivation with captopril enhanced vascular permeability, but mice doubly deficient in both C1-INH and B2R did not demonstrate any increased vascular permeability \[[@B24]\]. Intravenous administration of C1-INH seems to have an effect in acute treatment of ACEi AE, but large randomized placebo-controlled studies are not yet available \[[@B25], [@B26]\]. C1-INH plays a central role in the regulation of vascular permeability and in the suppression of inflammation \[[@B27]\]. It is a multipotent inhibitor in four physiological systems consisting of serine proteases and their effects: the complement, coagulation, fibrinolytic, and contact activation pathways \[[@B28], [@B29]\]. In the case of acute ACEi AE, a feedback loop might explain the increase in C1-INH activity: due to unknown factors, the iatrogenic inhibition of ACE in the degradation of bradykinin becomes clinically relevant, bradykinin levels become high, and edema is mediated. The high bradykinin levels could lead to an increase in C1-INH activity to improve its inhibitory function in bradykinin synthesis. As a trigger factor in the development of ACEi AE, inflammatory reactions have been discussed: strongly increased plasma levels of C-reactive protein were shown in patients presenting to the emergency room with ACEi AE \[[@B22]\]. However, the individual time course of onset has still not yet been clarified. The reason why only a small number of patients with an ACE inhibitor in their regular medication suffer from this side effect is another point that still remains unclear.

Currently, no laboratory value and no validated point-of-care diagnostic test are available to differentiate a bradykinin-mediated from a mast cell-mediated attack \[[@B30]\]. As we observed an interaction of ACE inhibition with C1-INH values in vitro, as well as increased C1-INH activity in patients with ACEi AE during attacks, this marker should be further evaluated.
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![**a** Summary of the effects on the C1-INH concentration. **b** Summary of the effects on C1-INH activity. Study visit 1: before first ACE inhibitor administration; study visit 2: 24 h after first ACE inhibitor administration; study visit 3: 4 weeks after first C1-INH administration. ACE, angiotensin-converting enzyme; C1-INH, C1-inhibitor; P, patient.](bmh-0004-0001-g03){#F3}

###### 

Data on patients with severe ACE inhibitor-induced angioedema

  Sex   ACE inhibitor   Dose, mg       Approximate period of ACE inhibitor treatment, years   ACE activity (normal range), U/L   C1-INH concentration (normal range), g/L   C1-INH activity (normal range), %
  ----- --------------- -------------- ------------------------------------------------------ ---------------------------------- ------------------------------------------ -----------------------------------
  F     ramipril        5 (1-0-1)      5                                                      \<12 (20--70)                      0.49 (0.17--0.44)                          \>150 (70--130)
  M     enalapril       10 (1-0-0)     15                                                     6.1 (8--52)                        0.48 (0.17--0.44)                          132 (70--130)
  M     ramipril        10 (0-1-0)     2                                                      5.2 (8--52)                        0.21 (0.17--0.44)                          139 (70--130)
  F     lisinopril      20 (1-0-1/2)   10                                                     6.1 (8--52)                        0.51 (0.17--0.44)                          \>150 (70--130)
  F     ramipril        5 (1-0-0)      12                                                     4.3 (8--52)                        0.32 (0.17--0.44)                          136 (70--130)
  M     ramipril        5 (1-0-1)      2                                                      6.0 (8--52)                        0.49 (0.17--0.44)                          150 (70--130)
  M     ramipril        5 (1-0-0)      4                                                      \<12 (20--70)                      not available                              111 (70--130)
  F     ramipril        5 (1-0-0)      6                                                      \<12 (20--70)                      0.38 (0.17--0.44)                          122 (70--130)

Normal ranges in ACE activity differ due to different laboratories. ACE, angiotensin-converting enzyme; C1-INH, Cl-inhibitor.

###### 

Results of the first study section

                                                         No captopril   +5 mg captopril   +25 mg captopril
  ------------------------------------------------------ -------------- ----------------- ------------------
  *Subject 1*                                                                             
  C1-INH concentration (normal range: 0.17--0.44), g/L   0.26           0.27              0.21
  C1-INH activity (normal range: 70--130), %             95             94                56
                                                                                          
  *Subject 2*                                                                             
  C1-INH concentration (normal range: 0.17--0.44), g/L   0.27           0.28              0.21
  C1-INH activity (normal range: 70--130), %             100            100               60
                                                                                          
  *Subject 3*                                                                             
  C1-INH concentration (normal range: 0.17--0.44), g/L   0.24           0.24              0.16
  C1-INH activity (normal range: 70--130), %             86             85                60
                                                                                          
  *Subject 4*                                                                             
  C1-INH concentration (normal range: 0.17--0.44), g/L   0.25           0.25              0.22
  C1-INH activity (normal range: 70--130), %             93             87                68
                                                                                          
  *Subject 5*                                                                             
  C1-INH concentration (normal range: 0.17--0.44), g/L   0.30           0.31              0.22
  C1-INH activity (normal range: 70--130), %             110            107               96

C1-INH, C1-inhibitor.
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